GM17509
LCL from B-Lymphocyte
Description:
BREAST CANCER, TYPE 1; BRCA1
|
Repository
|
NIGMS Human Genetic Cell Repository
|
| Subcollection |
Heritable Diseases
Hereditary Cancers |
| Class |
Heritable Cancer Syndromes and other Cancers |
|
Biopsy Source
|
Peripheral vein
|
|
Cell Type
|
B-Lymphocyte
|
|
Tissue Type
|
Blood
|
|
Transformant
|
Epstein-Barr Virus
|
|
Sample Source
|
LCL from B-Lymphocyte
|
|
Race
|
Filipino
|
|
Ethnicity
|
FILIPINO
|
|
Family Member
|
1
|
|
Relation to Proband
|
proband
|
|
Confirmation
|
Molecular characterization before cell line submission to CCR
|
|
Species
|
Homo sapiens
|
|
Common Name
|
Human
|
|
Remarks
|
|
| IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by Nucleoside Phosphorylase,Glucose-6-Phosphate Dehydrogenase, and Lactate Dehydrogenase Isoenzyme Electrophoresis |
| |
| Gene |
BRCA1 |
| Chromosomal Location |
17q21.31 |
| Allelic Variant 1 |
; BREAST CANCER, TYPE 1 |
| Identified Mutation |
IVS2-2delA |
| Remarks |
Clinically affected; diagnosed at age 41; paternal aunt diagnosed with breast and ovarian cancer in her fifties; donor subject carries a nucleotide deletion in a non-coding intervening sequence occurring within two nucleotides of the beginning of exon 3 (IVS2-2delA) in BRCA1; two variants were also identified: a BRCA1 variant G890R (GLY890ARG) which results in the substitution of arginine for glycine at amino acid position 890 of the BRCA1 protein and a BRCA2 variant [VAL2739ILE (V2739I)] which results in the substitution of isoleucine for valine at amino acid position 2739 of the BRCA2 protein. |
| dbSNP |
dbSNP ID: 15604 |
| Gene Cards |
BRCA1 |
| Gene Ontology |
GO:0000151 ubiquitin ligase complex |
|
GO:0003684 damaged DNA binding |
|
GO:0003713 transcription coactivator activity |
|
GO:0004842 ubiquitin-protein ligase activity |
|
GO:0005515 protein binding |
|
GO:0005615 extracellular space |
|
GO:0005622 intracellular |
|
GO:0005634 nucleus |
|
GO:0005667 transcription factor complex |
|
GO:0006357 regulation of transcription from Pol II promoter |
|
GO:0006359 regulation of transcription from Pol III promoter |
|
GO:0006978 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator |
|
GO:0008270 zinc ion binding |
|
GO:0008274 gamma-tubulin ring complex |
|
GO:0015631 tubulin binding |
|
GO:0016563 transcriptional activator activity |
|
GO:0016567 protein ubiquitination |
|
GO:0042127 regulation of cell proliferation |
|
GO:0042981 regulation of apoptosis |
|
GO:0045739 positive regulation of DNA repair |
|
GO:0045786 negative regulation of cell cycle |
|
GO:0046600 negative regulation of centriole replication |
| NCBI Gene |
Gene ID:672 |
| NCBI GTR |
113705 BREAST CANCER 1 GENE; BRCA1 |
|
604370 BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1; BROVCA1 |
| OMIM |
113705 BREAST CANCER 1 GENE; BRCA1 |
|
604370 BREAST-OVARIAN CANCER, FAMILIAL, SUSCEPTIBILITY TO, 1; BROVCA1 |
| Omim Description |
BREAST CANCER 1, EARLY-ONSETBREAST-OVARIAN CANCER, INCLUDED |
| |
BREAST CANCER, TYPE 1; BRCA1 |
| Split Ratio |
1:3 |
| Temperature |
37 C |
| Percent CO2 |
5% |
| Percent O2 |
AMBIENT |
| Medium |
Roswell Park Memorial Institute Medium 1640 with 2mM L-glutamine or equivalent |
| Serum |
15% fetal bovine serum Not Inactivated |
| Substrate |
None specified |
| Subcultivation Method |
dilution - add fresh medium |
| Supplement |
- |
|
|